OTC:ZVSA | Free Cash Flow | ZyVersa Therapeutics, Inc.

Free cash flow is operating cash flow less capital expenditure. FCF / net income requires positive matching-period earnings.

Available history
2021-06-30 to 2026-03-31
Data captured

Historical Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2026-03-31-$799,118.00
2025-12-31-$413,689.00
2025-03-31-$1.77M
2024-12-31-$1.21M
2024-03-31-$3.78M
2023-12-31-$2.79M
2023-03-31-$4.59M
2022-12-12-$779,816.00
2022-03-31-$98,165.00
2021-06-30-$48,075.00

Annual Free Cash Flow

DateOperating cash flowCapital expenditureFree cash flowFCF / net income
2025-12-31-$5.11M
2024-12-31-$7.52M
2023-12-31-$8.72M
2022-12-12-$1.49M

Research interface only. Not investment advice. Prices are a checked-in snapshot, not live quotes.